Drug Trial Radar · NCT04551053
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
177
Actual
Start
May 26, 2021
Primary completion
Aug 16, 2023
Study completion Aug 21, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
Conditions
- Myelofibrosis
- Primary Myelofibrosis
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
Interventions
parsaclisibDrug
parsaclisib will be administered QD orally
ruxolitinibDrug
ruxolitinib will be administered BID orally
placeboDrug
placebo will be administered QD orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants)Time frame: Baseline; Week 24
Locations
177 sites in 19 countries. Site status is shown where the registry gives one.
Sutter Health Alta Bates Summit Medical Center Absmc Alta Bates Summit Comprehensive Cancer Center
Berkeley, California
CCARE
Fresno, California
California Research Institute (Cri)
Los Angeles, California
Emad Ibrahim Md Inc
Redlands, California
Scripps Clinic
San Diego, California
Coastal Integrated Cancer Care - Cicc
San Luis Obispo, California
Stamford Hospital - Medical Oncology Hematology
Stamford, Connecticut
Georgetown University
Washington D.C., District of Columbia
Emory University
Atlanta, Georgia
Augusta University - Medical College of Georgia
Augusta, Georgia
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
University of Kansas Hospital Authority
Westwood, Kansas
Tulane University
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Midamerica Cancer Care
Kansas City, Missouri
New Jersey Hematology Oncology Associates Llc
Brick, New Jersey
Morristown Medical Center - Atlantic Health System
Morristown, New Jersey
Westchester Medical Center Advanced Oncology
Hawthorne, New York
Mount Sinai School of Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Advent Health Hendersonville Park Ridge Hospital Hendersonville
Clyde, North Carolina
Duke Cancer Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Science University
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Hillman Cancer Center
Pittsburgh, Pennsylvania
Baptist Cancer Center
Memphis, Tennessee
Texas Oncology - Medical City Dallas
Dallas, Texas
Texas Oncology - Baylor Sammons Cancer Center
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Renovatio Clinical
Houston, Texas
Kelsey Seybold Clinic
Houston, Texas
Providence Regional Medical Center Everett
Everett, Washington
Hanusch-Krankenhaus Wiener Gebietskrankenkasse
Vienna, Austria
A.Z. St.-Jan A.V.
Bruges, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
AZ Delta
Roeselare, Belgium
Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, Belgium
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.